Rights and permissions
About this article
Cite this article
Neoadjuvant trastuzumab + FEC for HER2-positive breast cancer. Inpharma Wkly. 1485, 9 (2005). https://doi.org/10.2165/00128413-200514850-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200514850-00025